Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
2.
Clinics ; 74: e941, 2019. tab
Article in English | LILACS | ID: biblio-989634

ABSTRACT

Human immunodeficiency virus (HIV) infection was considered a contraindication for solid organ transplantation (SOT) in the past. However, HIV management has improved since highly active antiretroviral therapy (HAART) became available in 1996, and the long-term survival of patients living with HIV has led many transplant programs to reevaluate their policies regarding the exclusion of patients with HIV infection. Based on the available data in the medical literature and the cumulative experience of transplantation in HIV-positive patients at our hospital, the aim of the present article is to outline the criteria for transplantation in HIV-positive patients as recommended by the Immunocompromised Host Committee of the Hospital das Clínicas of the University of São Paulo.


Subject(s)
Humans , HIV Infections/surgery , Organ Transplantation/standards , Hospitals, University/standards , Brazil , Patient Selection , Transplant Recipients
3.
Clinics ; 73: e344, 2018. tab
Article in English | LILACS | ID: biblio-952814

ABSTRACT

OBJECTIVES: Patients receiving treatment for tuberculosis are at risk of developing acute liver failure due to the hepatotoxicity of antitubercular drugs. We aimed to describe our experience with liver transplantation from deceased donors in this situation. METHODS: We identified patients undergoing transplantation for acute liver failure due to antitubercular drugs in our prospectively maintained database. RESULTS: Of 81 patients undergoing transplantation for acute liver failure, 8 cases were attributed to antitubercular drugs during the period of 2006-2016. Regarding the time of tuberculosis treatment until the onset of jaundice, patients were on antitubercular drugs for a mean of 64.7 days (21-155 days). The model for end-stage liver disease (MELD) score of patients ranged from 32 to 47 (median 38), and seven patients underwent transplantation under vasopressors. The 1-year survival was 50%. Three patients died during the week following transplantation due to septic shock (including a patient with acute liver failure due to hepatic/disseminated tuberculosis), and the remaining patient died 2 months after transplantation due to pulmonary infection. There were 2 cases of mild rejection and 1 case of moderate rejection. Of the surviving patients, all were considered cured of tuberculosis after alternative drugs were given. CONCLUSION: Patients arrived very sick and displayed poor survival after deceased donor transplantation.


Subject(s)
Humans , Female , Adolescent , Adult , Middle Aged , Young Adult , Tuberculosis/drug therapy , Liver Transplantation/methods , Liver Failure, Acute/surgery , Liver Failure, Acute/chemically induced , Antitubercular Agents/adverse effects , Time Factors , Tuberculosis/complications , Severity of Illness Index , Brain Diseases/etiology , Prospective Studies , Risk Factors , Liver Transplantation/mortality , Treatment Outcome , Liver Failure, Acute/mortality , Jaundice/etiology
4.
J. bras. nefrol ; 39(3): 341-344, July-Sept. 2017. graf
Article in English | LILACS | ID: biblio-893776

ABSTRACT

Abstract Granulicatella and Abiotrophia are genera of fastidious Gram-positive cocci commensal of the oral, genitourinary, and intestinal flora. We report the first case of infective endocarditis caused by Granulicatella sp. in a kidney transplant recipient. A 67-year-old male kidney transplant recipient was admitted to the hospital for investigation of fever, abdominal pain, and diarrhea. On physical examination, he was dehydrated. Laboratory tests identified impaired renal function (creatinine level of 15.5 mg/dl; reference, 3.0 mg/dl), metabolic acidosis, and electrolyte disturbances. Cryptosporidium sp. was identified as the cause of the diarrhea, and the infection was treated with nitazoxanide. On admission, cultures of blood, urine, and stool samples were negative. Echocardiography results were normal. Despite the antimicrobial treatment, the fever persisted. A transthoracic echocardiogram revealed infective endocarditis of the mitral valve, and Granulicatella spp. were isolated in blood cultures. Although the patient was treated with penicillin and amikacin, he evolved to septic shock of pulmonary origin and died. Infective endocarditis caused by Granulicatella sp. should be suspected in cases of culture-negative endocarditis.


Resumo Granulicatella e Abiotrophia são gêneros de cocos gram-positivos fastidiosos comensais das floras oral, genitourinária e intestinal. Relatamos o primeiro caso de endocardite infecciosa por Granulicatella sp. em paciente transplantado renal. Paciente do sexo masculino, 67 anos, foi admitido no hospital para investigação de febre, dor abdominal e diarreia. Ao exame físico encontrava-se desidratado. Exames laboratoriais identificaram piora de função renal (creatinina: 15,5mg/dL - níveis basais: 3mg/dL), acidose metabólica e distúrbios eletrolíticos. Cryptosporidium sp foi identificado como causa da diarréia e tal germe foi tratado com nitazoxanida. À admissão, hemoculturas, urocultura e coprocultura negativas além de ecocardiograma normal. A despeito do tratamento antimicrobiano, paciente persistiu febril. Um ecocardiograma transtorácico posterior foi realizado, revelando endocardite em válvula mitral, sendo então identificada em hemocultura Granulicatella sp. Apesar do tratamento com penicilina e amicacina, o paciente evoluiu com quadro de choque séptico de foco pulmonar e óbito. Endocardite infecciosa por Granulicatela sp. deve ser suspeitada em casos de endocardite com hemoculturas negativas.


Subject(s)
Humans , Male , Aged , Kidney Transplantation , Gram-Positive Bacterial Infections/diagnosis , Gram-Positive Bacterial Infections/drug therapy , Endocarditis, Bacterial/diagnosis , Endocarditis, Bacterial/drug therapy , Carnobacteriaceae , Postoperative Complications/diagnosis , Postoperative Complications/drug therapy , Fatal Outcome
5.
Mem. Inst. Oswaldo Cruz ; 110(1): 56-64, 03/02/2015. tab, graf
Article in English | LILACS | ID: lil-741619

ABSTRACT

Histology is the gold standard for diagnosing acute rejection and hepatitis C recurrence after liver transplantation. However, differential diagnosis between the two can be difficult. We evaluated the role of C4d staining and quantification of hepatitis C virus (HCV) RNA levels in liver tissue. This was a retrospective study of 98 liver biopsy samples divided into four groups by histological diagnosis: acute rejection in patients undergoing liver transplant for hepatitis C (RejHCV+), HCV recurrence in patients undergoing liver transplant for hepatitis C (HCVTx+), acute rejection in patients undergoing liver transplant for reasons other than hepatitis C and chronic hepatitis C not transplanted (HCVTx-). All samples were submitted for immunohistochemical staining for C4d and HCV RNA quantification. Immunoexpression of C4d was observed in the portal vessels and was highest in the HCVTx- group. There was no difference in C4d expression between the RejHCV+ and HCVTx+ groups. However, tissue HCV RNA levels were higher in the HCVTx+ group samples than in the RejHCV+ group samples. Additionally, there was a significant correlation between tissue and serum levels of HCV RNA. The quantification of HCV RNA in liver tissue might prove to be an efficient diagnostic test for the recurrence of HCV infection.


Subject(s)
Animals , Humans , Mice , Annexin A1/pharmacology , Macrophages/drug effects , Macrophages/immunology , Neutrophils/cytology , Neutrophils/immunology , Apoptosis , Actins/metabolism , Annexin A1/deficiency , Annexin A1/genetics , Annexin A1/immunology , Cyclic AMP-Dependent Protein Kinases/metabolism , Cyclic AMP/metabolism , Dexamethasone/pharmacology , In Vitro Techniques , /biosynthesis , Mice, Knockout , Macrophages/metabolism , Peptides , Phagocytosis/drug effects , Transforming Growth Factor beta/biosynthesis
6.
Br J Med Med Res ; 2014 Feb; 4(4): 1008-1013
Article in English | IMSEAR | ID: sea-174985

ABSTRACT

Introduction: Selective laser trabeculoplasty (SLT) (Lumenis, Santa Clara, CA) was developed in 1999 as a means to lower IOP in patients with glaucoma. It is a relatively safe procedure. We report a rare side effect of anterior chamber shallowing with myopic following SLT. Case Presentation: A 48 year-old white female who underwent SLT OD developed a 4- diopter myopic shift and anterior chamber shallowing 1 week following SLT. Both the anterior chamber shallowing and the myopic shift resolved within 5 weeks. Conclusion: Anterior chamber shallowing and myopic shift following SLT is a rare side effect but is reversible. Physicians and patients should be aware of this potential side effect of SLT.

7.
Br J Med Med Res ; 2014 Jan; 4(1): 279-287
Article in English | IMSEAR | ID: sea-174893

ABSTRACT

Aims: Selective laser trabeculoplasty (SLT) (Lumenis, Santa Clara, CA) was developed in 1999 as a means to lower IOP in patients with glaucoma. It is a relatively safe procedure. We report a rare side effect of corneal opacity and stromal haze with corneal thinning and hyperopic shift following SLT. Presentation of Case: Case report. Results: A 50 year-old Asian male who underwent SLT OD developed mild corneal edema and slightly elevated intraocular pressure (IOP) one day after procedure. He was prescribed anti-inflammatory drops. One week afterwards, he developed a small corneal abrasion centrally. He was given topical antibiotics and asked to continue antiinflammatory drops. On postoperative day 8, his corneal abrasion healed, but he developed stromal corneal haze. Topical steroids were begun. By postoperative week #2, his visual acuity and stromal haze had improved. His corneal thickness decreased from 600 μms to 468 μms. After one year, he had almost complete resolution of his corneal pathology but had residual corneal thinning and flattening. Discussion: Corneal stromal haze following SLT is a rare side effect. This can result in corneal scarring with corneal thinning and a hyperopic shift due to corneal flattening. Physicians and patients should be aware of this potentially vision threatening side effect. Conclusion: More studies are needed to identify risk factors for the development of corneal pathology following selective laser trabeculoplasty.

8.
Braz. j. infect. dis ; 17(1): 41-47, Jan.-Feb. 2013. ilus, tab
Article in English | LILACS, SES-SP | ID: lil-665773

ABSTRACT

OBJECTIVES: To assess the virologic and immunological response of darunavir/ritonavir plus optimized background therapy in highly antiretroviral-experienced HIV-infected patients in Brazil. METHODS: Prospective cohort study carried out in a tertiary center in Sao Paulo, Brazil. Three-class antiretroviral-experienced patients with confirmed virologic failure began darunavir/ritonavir plus optimized background therapy (nucleoside/tide reverse transcriptase inhibitors ± raltegravir ± enfuvirtide ± maraviroc) after performing a genotypic resistance assay. Clinical evaluation and laboratory tests were collected at baseline and at weeks 12, 24, and 48. Multivariate analysis was performed to identify predictors of virologic response at 48 weeks. RESULTS: Ninety-two patients were included. The median of darunavir resistant mutation was 1 (range 0-6). The median genotypic sensitivity score in the optimized background therapy was 2 (interquartile range 1-2). At week 48, 83% (95% CI: 75-90%) had an HIV RNA level <50 copies/mL and the median CD4 cell count was 301 (interquartile range 224-445) cells/mm³. Baseline HIV RNA >100 000 copies/mL was inversely associated with virologic success at week 48 (HR: 0.22, 95% CI: 0.06-0.85, p = 0.028). CONCLUSIONS: Darunavir/ritonavir plus optimized background therapy was a highly effective salvage regimen under clinical routine conditions in a referral center in Brazil, which is similar to the reported in high-income countries.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , HIV-1 , Anti-HIV Agents/therapeutic use , Drug Resistance, Viral/genetics , HIV Infections/drug therapy , Mutation/genetics , Ritonavir/therapeutic use , Sulfonamides/therapeutic use , HIV-1 , Antiretroviral Therapy, Highly Active , Brazil , Cohort Studies , Drug Therapy, Combination/methods , Genotype , HIV Infections/virology , Prospective Studies , Time Factors , Viral Load
9.
Braz. j. infect. dis ; 15(3): 245-248, May-June 2011. tab
Article in English | LILACS, SES-SP | ID: lil-589956

ABSTRACT

Information about resistance profile of darunavir (DRV) is scarce in Brazil. Our objectives were to estimate the prevalence of DRV resistance mutations in patients failing protease inhibitors (PI) and to identify factors associated with having more DRV resistance mutations. All HIV-infected patients failing PI-based regimens with genotyping performed between 2007 and 2008 in a referral teaching center in São Paulo, Brazil, were included. DRV-specific resistance mutations listed by December 2008 IAS-USA panel update were considered. Two Poisson regression models were constructed to assess factors related to the presence of more DRV resistance mutations. A total of 171 HIV-infected patients with available genotyping were included. The number of patients with lopinavir, saquinavir, and amprenavir used in previous regimen were 130 (76 percent), 83 (49 percent), and 35 (20 percent), respectively. The prevalence of major DRV resistance mutations was 50V: 5 percent; 54M: 1 percent; 76V: 4 percent; 84V: 15 percent. For minor mutations, the rates were 11I: 3 percent; 32I: 7 percent; 33F: 23 percent; 47V: 6 percent; 54L: 6 percent; 74P: 3 percent; 89V: 6 percent. Only 11 (6 percent) of the genotypes had > 3 DRV resistance mutations. In the clinical model, time of HIV infection of > 10 years and use of amprenavir were independently associated with having more DRV resistance mutations. In the genotyping-based model, only total number of PI resistance mutations was associated with our outcome. In conclusion, the prevalence of DRV mutations was low. Time of HIV infection, use of amprenavir and total number of PI resistance mutations were associated with having more DRV mutations.


Subject(s)
Adult , Female , Humans , Male , HIV-1 , Drug Resistance, Viral/genetics , HIV Infections/virology , HIV Protease Inhibitors/therapeutic use , Mutation/genetics , Sulfonamides/therapeutic use , HIV-1 , Brazil , Genotype , HIV Infections/drug therapy , Prevalence , Viral Load
10.
Braz. j. infect. dis ; 10(2): 132-138, Apr. 2006. tab
Article in English | LILACS | ID: lil-431986

ABSTRACT

Mycophenolate mofetil (MMF) is currently used for prophylaxis of acute rejection in solid organ transplantation. There have been diverging reports regarding an association between MMF and the risk of cytomegalovirus (CMV) infection. We reviewed the main published studies in an attempt to clarify the association between the use of MMF and the risk, frequency and severity of CMV infections. In a search of the Medline database with the terms "mycophenolate" and "cytomegalovir*", 42 articles were found to be relevant; among these, 29 articles were thoroughly analyzed. The first studies on MMF in renal transplantation already showed a tendency towards an association between this drug and the occurrence of CMV disease. Further studies were designed specifically to study this association; with the conclusion that an immunosuppressive regimen containing MMF increases the likelihood of CMV disease. Most studies were performed with kidney transplant recipients. We conclude that the use of MMF apparently increases the incidence of CMV disease in renal transplant patients; however, further studies are needed to confirm this association.


Subject(s)
Humans , Cytomegalovirus Infections/chemically induced , Immunosuppressive Agents/adverse effects , Kidney Transplantation , Liver Transplantation , Mycophenolic Acid/analogs & derivatives , Cytomegalovirus Infections/epidemiology , Graft Rejection/prevention & control , Incidence , Mycophenolic Acid/adverse effects , Risk Factors , Severity of Illness Index
11.
Rev. Hosp. Clin. Fac. Med. Univ. Säo Paulo ; 58(4): 207-214, 2003. tab, graf
Article in English | LILACS | ID: lil-347109

ABSTRACT

Considering the relevance of AIDS/tuberculosis comorbidity worldwide, especially in Brazil, this study was developed to describe the clinical and epidemiological features of the comorbid cases identified from 1989 to 1997 by the epidemiology service of the Hospital das Clínicas of the Universidade de Säo Paulo. METHODS: Databases containing information on all identified AIDS/tuberculosis cases cared for at the hospital were used to gather information on comorbid cases. RESULTS: During the period, 559 patients were identified as presenting with AIDS/tuberculosis comorbidity. Risk behavior for AIDS was primarily heterosexual contact (38.9 percent), followed by intravenous drug use (29.3 percent) and homosexual/bisexual contact (23.2 percent). Regarding clinical features, there were higher rates of extrapulmonary tuberculosis when compared to tuberculosis without comorbidity. There was an increase in reporting of AIDS by ambulatory units during the period. Epidemiologically, there was a decrease in the male/female ratio, a predominance in the 20 to 39 year-old age group, and a majority of individuals who had less than 8 years of schooling and had low professional qualifications. CONCLUSIONS: High rates of AIDS/tuberculosis cases at our hospital indicate the need for better attention towards early detection of tuberculosis, especially in its extrapulmonary form. Since the population that attends this hospital tends to be of a lower socioeconomic status, better management of AIDS and tuberculosis is required to increase the rates of treatment adherence and thus lower the social costs


Subject(s)
Adolescent , Adult , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Middle Aged , AIDS-Related Opportunistic Infections/epidemiology , Acquired Immunodeficiency Syndrome/epidemiology , Tuberculosis/epidemiology , Age Distribution , Brazil/epidemiology , Comorbidity , Educational Status , Incidence , Risk Factors , Sex Distribution
SELECTION OF CITATIONS
SEARCH DETAIL